Cargando…

Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with Cytomegalovirus

Human cytomegalovirus (HCMV) is a significant pathogen in immunocompromised individuals, with the potential to cause fatal pneumonitis and colitis, as well as increasing the risk of organ rejection in transplant patients. With the advent of new anti-HCMV drugs there is therefore considerable interes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Houldcroft, Charlotte J., Bryant, Josephine M., Depledge, Daniel P., Margetts, Ben K., Simmonds, Jacob, Nicolaou, Stephanos, Tutill, Helena J., Williams, Rachel, Worth, Austen J. J., Marks, Stephen D., Veys, Paul, Whittaker, Elizabeth, Breuer, Judith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016526/ https://www.ncbi.nlm.nih.gov/pubmed/27667983 http://dx.doi.org/10.3389/fmicb.2016.01317

Ejemplares similares

Human cytomegalovirus haplotype reconstruction reveals high diversity due to superinfection and evidence of within-host recombination
por: Cudini, Juliana, et al.
Publicado: (2019)

Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus
por: Gandhi, Ronak G, et al.
Publicado: (2022)

The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein
por: Shannon-Lowe, Claire D, et al.
Publicado: (2010)

Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient
por: Schubert, Axel, et al.
Publicado: (2013)

Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection
por: Chou, Sunwen, et al.
Publicado: (2020)

Maribavir for Cytomegalovirus Treatment in the Real World—Not a Silver Bullet
por: Fung, Monica, et al.
Publicado: (2022)

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial( )
por: Avery, Robin K, et al.
Publicado: (2021)

Correction to: Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
Publicado: (2023)

Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus
por: Sun, Kefeng, et al.
Publicado: (2023)

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
por: Papanicolaou, Genovefa A, et al.
Publicado: (2019)

1746. Prevalence and Resistance Patterns of Cytomegalovirus Viremia in Immunocompromised Patients
por: Kim, Edward, et al.
Publicado: (2019)

S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
por: Duarte, Rafael F, et al.
Publicado: (2023)

21. Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results
por: Pereira, Marcus, et al.
Publicado: (2021)

Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
por: Venturini, Cristina, et al.
Publicado: (2021)

Synthesis of New Imidazopyridine Nucleoside Derivatives Designed as Maribavir Analogues
por: Papadakis, Georgios, et al.
Publicado: (2020)

Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir
por: Gill, Rachel B, et al.
Publicado: (2009)

Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection
por: Faure Bardon, Valentine, et al.
Publicado: (2020)

Cytomegalovirus pneumonitis in an immunocompromised host
por: Balakrishnan, Rabitha, et al.
Publicado: (2022)

Cytomegalovirus Esophagitis in an Immunocompromised Patient
por: Ali, Adya A, et al.
Publicado: (2023)

Cytomegalovirus infection of the thyroid in immunocompromised adults.
por: Frank, T. S., et al.
Publicado: (1987)

Cytomegalovirus Cutaneous Infection in an Immunocompromised Patient
por: Fasanya, Adebayo A, et al.
Publicado: (2016)

Pathogenesis of human cytomegalovirus in the immunocompromised host
por: Griffiths, Paul, et al.
Publicado: (2021)

Cytomegalovirus Hepatitis in Immunocompetent and Immunocompromised Hosts
por: Da Cunha, Teresa, et al.
Publicado: (2021)

Effects of Maribavir on P‐Glycoprotein and CYP2D6 in Healthy Volunteers
por: Song, Ivy H., et al.
Publicado: (2019)

Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study
por: Ilic, Katarina, et al.
Publicado: (2020)

Staphylococcus aureus – antimicrobial resistance and the immunocompromised child
por: McNeil, J Chase
Publicado: (2014)

Tales from the crypt and coral reef: the successes and challenges of identifying new herpesviruses using metagenomics
por: Houldcroft, Charlotte J., et al.
Publicado: (2015)

Cytomegalovirus Retinitis in an Immunocompromised Infant: A Case Report and Review of the Literature
por: Mota, A., et al.
Publicado: (2011)

Islands of linkage in an ocean of pervasive recombination reveals two-speed evolution of human cytomegalovirus genomes
por: Lassalle, Florent, et al.
Publicado: (2016)

Gastric Outlet Obstruction due to Cytomegalovirus Infection in an Immunocompromised Patient
por: Panteris, Vasileios, et al.
Publicado: (2009)

Strongyloides stercoralis Hyperinfection and Concomitant Cytomegalovirus Gastroenteritis in an Immunocompromised Host
por: Crowe, Brooks R., et al.
Publicado: (2019)

Cytomegalovirus epithelitis in an immunocompromised patient of T-cell acute lymphoblastic leukemia
por: Agashe, Prachi, et al.
Publicado: (2020)

Cytomegalovirus infection presenting as an isolated petechial eruption in an immunocompromised patient
por: Raman, Justin, et al.
Publicado: (2021)

The CD4+ T Cell Response to Human Cytomegalovirus in Healthy and Immunocompromised People
por: Lim, Eleanor Y., et al.
Publicado: (2020)

Cytomegalovirus colitis in an immunocompromised patient presenting with massive lower gastrointestinal bleeding
por: Surapatpichai, Malisa, et al.
Publicado: (2022)

Testing for Cytomegalovirus Among Individuals Who Were Immunocompromised, 2018-2022
por: Jain, Purva, et al.
Publicado: (2023)

Clinical and biological insights from viral genome sequencing
por: Houldcroft, Charlotte J., et al.
Publicado: (2017)

Azole Resistance of Aspergillus fumigatus in Immunocompromised Patients with Invasive Aspergillosis
por: van der Linden, Jan W.M., et al.
Publicado: (2016)

Mouse Model of Cytomegalovirus Disease and Immunotherapy in the Immunocompromised Host: Predictions for Medical Translation that Survived the “Test of Time”
por: Reddehase, Matthias J., et al.
Publicado: (2018)

Therapeutic Drug Monitoring of Ganciclovir Treatment for Cytomegalovirus Infections Among Immunocompromised Children
por: Stockmann, Chris, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dqr2gcoait5rqidmrb930eirn2